Auryxia
Author: Michael Haydock
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Auryxia (ferric citrate; Keryx Biopharmaceuticals/Japan Tobacco/Torii Pharmaceutical) is a novel oral ferric iron form with hematinic activity, approved for the treatment of anemia in chronic kidney disease. The drug dissociates into ferric iron and citrate after administration. Ferric iron is transported to erythroid precursor cells to be incorporated into hemoglobin, and also binds dietary phosphate in the gastrointestinal tract, precipitating as ferric phosphate. This compound is excreted, decreasing the phosphate concentration in the serum.
TABLE OF CONTENTS
4 Product Profiles
4 Auryxia : Anemia in chronic kidney disease
LIST OF FIGURES
7 Figure 1: Auryxia for anemia in chronic kidney disease – SWOT analysis
8 Figure 2: Datamonitor Healthcare’s drug assessment summary of Auryxia for anemia in chronic kidney disease
9 Figure 3: Datamonitor Healthcare’s drug assessment summary of Auryxia for anemia in chronic kidney disease
11 Figure 4: Auryxia sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015–24
LIST OF TABLES
5 Table 1: Auryxia drug profile
6 Table 2: Auryxia Phase III data in anemia in chronic kidney disease
6 Table 3: Auryxia Phase II data in anemia in chronic kidney disease
12 Table 4: Auryxia sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Aranesp 
Sign up to the